| Literature DB >> 34789482 |
Anthony R Mato1, Matthew S Davids2, Jeff Sharman3, Lindsey E Roeker1, Neil Kay4, Arnon P Kater5, Kerry Rogers6, Meghan C Thompson1, Joanna Rhodes7, Andre Goy8, Alan Skarbnik9, Stephen J Schuster7, Constantine S Tam10, Toby A Eyre11, Susan O'Brien12, Chadi Nabhan13, Nicole Lamanna14, Clare Sun15, Mazyar Shadman16, John M Pagel17, Chaitra Ujjani16, Danielle Brander18, Catherine C Coombs19, Nitin Jain8, Chan Y Cheah20, Jennifer R Brown2, John F Seymour10, Jennifer A Woyach6.
Abstract
The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance to multiple classes. Symptomatic patients previously treated with a BTK inhibitor (BTKi) and venetoclax represent a new and rapidly growing unmet need in CLL. Here, we define unmet needs in a modern treatment context. We also critically review the literature for PI3K inhibitors and chemoimmunotherapy and lack of data to support their utility following BTKis and venetoclax. Finally, we suggest opportunities to ensure the continued innovation for patients with CLL. ©2021 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2022 PMID： 34789482 PMCID： PMC9253788 DOI： 10.1158/1078-0432.CCR-21-1237
Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 13.801